Roger Song, an analyst from Jefferies, maintained the Buy rating on United Therapeutics. The associated price target was raised to $575.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roger Song has given his Buy rating due to a combination of factors that highlight United Therapeutics’ strong growth potential and strategic initiatives. The company has demonstrated robust revenue growth, particularly driven by the success of Tyvaso, which continues to expand its market presence despite competitive pressures. United Therapeutics has set an ambitious target of achieving a $1 billion quarterly run rate by 2027, which exceeds consensus expectations and is supported by the anticipated launch of IPF treatments.
Furthermore, the company’s openness to strategic partnerships, especially for Tyvaso and ralinepag, indicates a proactive approach to expanding its market reach. The promising results from the TETON-2 trial and the potential for expedited FDA review for IPF treatments further bolster the company’s growth prospects. Additionally, the company’s ability to maintain strong performance despite competitive challenges, along with its strategic pipeline developments, reinforces the positive outlook for United Therapeutics’ stock.
Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Inovio Pharmaceuticals, and Nektar Therapeutics. According to TipRanks, Song has an average return of -8.1% and a 36.94% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $525.00 price target.